FUJIFILM Diosynth Biotechnologies
About FUJIFILM Diosynth Biotechnologies
Categories
-
GB -
2015On CPHI since
-
1000 - 4999Employees
Company types
Products from FUJIFILM Diosynth Biotechnologies (3)
-
Product Analytical development
Fujifilm Diosynth Biotechnologies offers wide range of biopharmaceutical contract manufacturing services which includes analytical development. It belongs to process devlopment services category. It includes the target protein and related species, process impurities, protein potency, etc. -
Product Ancillary studies
Fujifilm Diosynth Biotechnologies offers wide range of biopharmaceutical contract manufacturing services which includes ancillary studies. It belongs to analytical solutions services category. It is usefull in support the product characterization changes occurring during the development of your drug, and v... -
Product Apollo™ mammalian expression platform
Fujifilm Diosynth Biotechnologies offers wide range of biopharmaceutical contract manufacturing services which includes apollo™ mammalian expression platform . It belongs to process devlopment services category. It includes cell line for life, rapid clinical material, early representative material, op...
FUJIFILM Diosynth Biotechnologies Resources (6)
-
News Fujifilm Diosynth Biotechnologies to expand biologics manufacturing capacity
As part of $850 million investment package, CDMO will double US cell culture production for recombinant vaccines and increase UK gene therapy production tenfold -
News Pandemic creates extra demand for CDMO services but investment decisions remain key to success
While the COVID-19 pandemic has created even greater demand for partnerships, CDMOs need to be aware that the needle has shifted, creating both opportunities and challenges and changing how the services industry does business -
News GSK to manufacture 60 million doses of Novavax vaccine for the UK
Pharma company will provide fill and finish manufacturing capacity at its Barnard Castle facility as early as the beginning of May 2021 -
News Fujifilm names North Carolina as location for $2 billion large-scale cell manufacturing site
CDMO subsidiary Fujifilm Diosynth Biotechnologies will operate the site which is expected to be operational in 2025 -
News Fujifilm invests $928 million to expand CDMO's biologics production facility in Denmark
Investment will double the site's drug substance manufacturing capacity and will expand its capabilities to include fill/finish, and enhance its current assembly, labeling and packaging services. -
News FDB to triple UK microbial production capacity as Fujifilm commits to $83 million investment
Fujifilm Diosynth Biotechnologies will triple microbial production capacity at its UK Teesside facility after joint owner Fujifilm Corporation pledged to invest 9 billion yen (USD83 million) in the biologics focused CDMO.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance